Mallinckrodt Inc. Signs Distribution Agreement With Amneal Pharmaceuticals

Published: Aug 20, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

HAZELWOOD, Mo.--(BUSINESS WIRE)--Mallinckrodt (NYSE: MNK) announced today that it has entered into an agreement with Amneal Pharmaceuticals LLC to distribute to addiction treatment centers its Buprenorphine HCl and Naloxone HCl Dihydrate Sublingual Tablets (CIII), a generic version of Suboxone®, manufactured in Amneal’s Hauppauge, New York, facility. The product is a prescription medication indicated for the maintenance treatment of opioid dependence. The contract covers a period of three years, with an option to extend.

Help employers find you! Check out all the jobs and post your resume.

Back to news